Patients across the United Kingdom are struggling to obtain the weight-loss and diabetes drug Mounjaro as demand surges ahead of a sharp price increase set for September.
Eli Lilly and Co. (NYSE:LLY), the U.S. manufacturer, confirmed it will raise Mounjaro's list price by up to 170%, pushing the cost of the highest monthly dose from £122 to £330. The announcement prompted pharmacies to restrict supply, prioritizing existing patients and warning against panic buying, as reported by BBC News
